Invasive Pneumococcal Disease in New Zealand, 2010

Appendix 11. Trends in penicillin resistance, cefotaxime resistance and multidrug resistance among pneumococcifrom invasive disease, 2001-2010YearNumberofisolatesPenicillinCefotaximeMeningitis 1 Non-meningitis 2 Oral 3 Meningitis 4 Non-meningitis 5%S %R %S %I %R %S %I %R %S %I %R %S %I %R2001 537 87.3 12.7 99.1 0.9 0.0 87.3 8.8 3.9 95.2 3.4 1.5 98.5 0.6 0.9 3.52002 490 83.1 16.9 99.6 0.4 0.0 83.1 13.5 3.5 94.9 3.1 2.0 98.0 0.4 1.6 5.12003 523 83.6 16.4 98.9 1.2 0.0 83.6 9.0 7.5 88.0 8.4 3.6 96.4 1.9 1.7 7.12004 545 81.8 18.2 98.5 1.5 0.0 81.8 8.1 10.1 87.2 9.7 3.1 96.9 2.4 0.7 5.32005 492 82.9 17.1 98.6 1.4 0.0 82.9 10.0 7.1 90.5 6.5 3.1 97.0 1.7 1.4 6.72006 522 84.1 15.9 98.9 1.0 0.2 84.1 8.1 7.9 90.0 7.3 2.7 97.3 1.7 1.0 4.42007 555 77.7 22.3 99.1 0.7 0.2 77.7 16.0 6.3 86.0 11.4 2.7 97.3 1.1 1.6 6.12008 630 77.9 22.1 99.5 0.5 0.0 77.9 14.6 7.5 84.9 10.0 5.1 94.9 3.0 2.1 5.92009 665 82.3 17.7 99.7 0.3 0.0 82.3 12.3 5.4 91.1 6.9 2.0 98.1 1.4 0.6 5.32010 514 81.9 18.1 99.0 1.0 0.0 81.9 12.1 6.0 91.8 6.2 1.9 98.1 0.4 1.6 5.41 Penicillin meningitis interpretations: susceptible (S), MIC ≤0.06 mg/L; resistant (R), MIC ≥0.12 mg/L; no intermediate category.2 Penicillin non-meningitis (parenteral treatment) interpretations: susceptible (S), MIC ≤2 mg/L; intermediate (I), MIC 4 mg/L; resistant (R), MIC ≥8 mg/L.3 Penicillin non-meningitis (oral treatment) interpretations: susceptible (S), MIC ≤0.06 mg/L; intermediate (I), MIC 0.12-1 mg/L; resistant (R), MIC ≥2 mg/L.4 Cefotaxime meningitis interpretations: susceptible (S), MIC ≤0.5 mg/L; intermediate (I), MIC 1 mg/L; resistant (R), MIC ≥2 mg/L.5 Cefotaxime non-meningitis interpretations: susceptible (S), MIC ≤1 mg/L; intermediate (I), MIC 2 mg/L; resistant (R), MIC ≥4 mg/L.6 Multidrug resistant, that is, resistant to penicillin (meningitis interpretation) and three additional antibiotics.MDR 6Invasive pneumococcal disease 37 September 2011in NZ, 2010